EMA Authorised: Alecensa (alectinib hydrochloride) — Roche Registration GmbH

View source ↗

Summary

The EMA authorised Alecensa (alectinib hydrochloride) for non-small cell lung carcinoma, with Roche Registration GmbH as the MAH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Roche Registration GmbH. Decision date: 29/01/2026